When was Capsida founded?

Capsida was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Capsida located?

Capsida is headquartered in Newbury Park, United States. It is registered at Thousand Oaks, California.

How many employees does Capsida have?

As of Apr 30, 2026, the latest employee count at Capsida is 54.

Is Capsida a funded company?

Capsida is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Apr 29, 2021.

When was the latest funding round of Capsida?

Capsida's latest funding was a $***** Series A round on Apr 29, 2021, with participation from 2 investors. Its primary sector is Gene Therapy. In United States, the Gene Therapy sector has seen $778M in funding in 2026 to date.

Where does Capsida rank among its competitors?

Capsida ranks 429th amongst 2924 active competitors, of which 997 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Capsida?

Capsida's top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Immuneel secured the most recent funding round in June, 2026.

Capsida - 2026 Company Profile, Team, Funding & Competitors

Capsida is a series A company based in Newbury Park (United States), founded in 2019 by Viviana Gradinaru, Nicholas Flytzanis and Nick Goeden. It operates as a Developer of next-generation AAV platform for gene therapies. Capsida has raised $50M in funding from Versant Ventures and Westlake Village Biopartners. The company has 2924 active competitors, including 997 funded and 714 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.

Company Details

Developer of next-generation AAV platform for gene therapies. The adeno-associated virus engineering platform generates capsids that target the specific tissues and cells in the diseased organ. These therapies are used for genetic disorders in both the CNS and non-CNS indications.

Website: capsida.com
Social
Registered Address: Thousand Oaks, California

Key Metrics

Founded Year

2019

Location

Newbury Park, United States

Stage

Series A

Total Funding

$50M in 1 round

Latest Funding Round

Series A, Apr 29, 2021, $*****

Investors

Versant Ventures & 2 more

Ranked

429^th among 2924 active competitors

Employee Count

54 as on Apr 30, 2026

Similar Companies

Jazz Pharmaceuticals & 665 more

View Capsida's full profile

Capsida is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CAPSIDA BIOTHERAPEUTICS, INC. CIN: 834673583 , United States, Active	Dec 31, 1999	-	116 (As on Dec 31, 2024)	-

Capsida has raised a total funding of $50M over 1 round. Its latest funding round was a Series A round on Apr 29, 2021 for $*****. 2 investors participated in its latest round. Capsida has 3 institutional investors.

Here is the list of recent funding rounds of Capsida:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 29, 2021	1265833	Series A	4782696	1486458	8528814	2199417

Access funding benchmarks and valuations. Sign up today!

View details of Capsida's funding rounds and investors

The founders of Capsida are Viviana Gradinaru, Nicholas Flytzanis and Nick Goeden. Robert M Cuddihy is the CEO of Capsida.

Here are the details of Capsida's key team members:

Viviana Gradinaru: Co-Founder of Capsida.
Contact Info: 1 email address
Nicholas Flytzanis: Co-Founder & VP of Capsida.
Contact Info: 1 email address
Nick Goeden: Co-Founder of Capsida.
Contact Info: 1 email address
Robert M Cuddihy: CEO of Capsida.

View details of Capsida's Founder profiles and Board Members

Capsida's employee count trend

Capsida has 54 employees as of Apr 26. Here is Capsida's employee count trend over the years:

Uncover Capsida's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Capsida include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Capsida, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	73/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
7th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
8th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
429th	Capsida 2019, Newbury Park (United States), Series A	Developer of next-generation AAV platform for gene therapies	$50M	AbbVie, Versant Ventures & 1 others	53/100